Arrowhead Pharmaceuticals, Inc.
Could not find a ticker for this position, may be a filing error
A developer of RNA-interference medicines that silence disease-causing genes, Arrowhead's first FDA-approved drug, REDEMPLO, treats a rare condition called familial chylomicronemia syndrome by lowering triglycerides. The company began in 1989 as Arrowhead Research Corporation, a tech incubator that commercialized university patents, before pivoting to gene-silencing medicines after buying Roche's RNAi assets in 2011. Its name was chosen to symbolize a focused, forward-moving direction.
Convertible Senior Notes due 2032 (0%)
Item 4 of the Original Schedule 13D is hereby amended by adding the following: On August 13, 2025, Sarepta Investments sold 9,265,312 shares of the Issuer's Common Stock at a price of $18.79 per share in a privately negotiated block trade pursuant to Rule 144 of the Securities Act of 1933, as amended (the "Secondary Sale"). Also on August 13, 2025, concurrently with the Secondary Sale, Sarepta, Sarepta Investments and the Issuer entered into a Letter Agreement (the "Letter Agreement") pursuant to which the Issuer agreed to redeem and acquire from Sarepta Investments 2,660,989 shares of the Issuer's Common Stock (the "Redemption") in satisfaction of the obligation of Sarepta to pay the Issuer $49,999,983.31 of the DM1 First Development Milestone Payment (as such term is defined in Section 8.3.1(a)(i) of the Collaboration Agreement). The foregoing description of the Letter Agreement is not complete and is subject to and qualified in its entirety by reference to the full text of such agreement, which is attached as Exhibit 99.5 hereto and incorporated herein by reference.
Item 4 of the Original Schedule 13D is hereby amended by adding the following: On August 13, 2025, Sarepta Investments sold 9,265,312 shares of the Issuer's Common Stock at a price of $18.79 per share in a privately negotiated block trade pursuant to Rule 144 of the Securities Act of 1933, as amended (the "Secondary Sale"). Also on August 13, 2025, concurrently with the Secondary Sale, Sarepta, Sarepta Investments and the Issuer entered into a Letter Agreement (the "Letter Agreement") pursuant to which the Issuer agreed to redeem and acquire from Sarepta Investments 2,660,989 shares of the Issuer's Common Stock (the "Redemption") in satisfaction of the obligation of Sarepta to pay the Issuer $49,999,983.31 of the DM1 First Development Milestone Payment (as such term is defined in Section 8.3.1(a)(i) of the Collaboration Agreement). The foregoing description of the Letter Agreement is not complete and is subject to and qualified in its entirety by reference to the full text of such agreement, which is attached as Exhibit 99.5 hereto and incorporated herein by reference.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 13G/APassive | 9.64% | 13.82M | Aug 14, 2026 |
| Behzad Aghazadeh | 13G/APassive | 9.64% | 13.82M | Aug 14, 2026 |
| Vanguard Portfolio Management | 13G/APassive | 4.53% | 6.38M | Jul 31, 2026 |
| BlackRock, Inc. | 13G/APassive | 10.1% | 14.23M | Jul 27, 2026 |
| FMR LLC | 13GPassive | 5.2% | 7.35M | May 6, 2026 |
| Abigail P. Johnson | 13GPassive | 5.2% | 7.35M | May 6, 2026 |
| Vanguard Capital Management | 13GPassive | 5.05% | 7.08M | Apr 29, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| Sarepta Therapeutics, Inc. | 13D/AActivist | 0% | 0 | Aug 15, 2025 |
Item 4 of the Original Schedule 13D is hereby amended by adding the following: On August 13, 2025, Sarepta Investments sold 9,265,312 shares of the Issuer's Common Stock at a price of $18.79 per share in a privately negotiated block trade pursuant to Rule 144 of the Securities Act of 1933, as amended (the "Secondary Sale"). Also on August 13, 2025, concurrently with the Secondary Sale, Sarepta, Sarepta Investments and the Issuer entered into a Letter Agreement (the "Letter Agreement") pursuant to which the Issuer agreed to redeem and acquire from Sarepta Investments 2,660,989 shares of the Issuer's Common Stock (the "Redemption") in satisfaction of the obligation of Sarepta to pay the Issuer $49,999,983.31 of the DM1 First Development Milestone Payment (as such term is defined in Section 8.3.1(a)(i) of the Collaboration Agreement). The foregoing description of the Letter Agreement is not complete and is subject to and qualified in its entirety by reference to the full text of such agreement, which is attached as Exhibit 99.5 hereto and incorporated herein by reference. | ||||
| Sarepta Therapeutics Investments, Inc. | 13D/AActivist | 0% | 0 | Aug 15, 2025 |
Item 4 of the Original Schedule 13D is hereby amended by adding the following: On August 13, 2025, Sarepta Investments sold 9,265,312 shares of the Issuer's Common Stock at a price of $18.79 per share in a privately negotiated block trade pursuant to Rule 144 of the Securities Act of 1933, as amended (the "Secondary Sale"). Also on August 13, 2025, concurrently with the Secondary Sale, Sarepta, Sarepta Investments and the Issuer entered into a Letter Agreement (the "Letter Agreement") pursuant to which the Issuer agreed to redeem and acquire from Sarepta Investments 2,660,989 shares of the Issuer's Common Stock (the "Redemption") in satisfaction of the obligation of Sarepta to pay the Issuer $49,999,983.31 of the DM1 First Development Milestone Payment (as such term is defined in Section 8.3.1(a)(i) of the Collaboration Agreement). The foregoing description of the Letter Agreement is not complete and is subject to and qualified in its entirety by reference to the full text of such agreement, which is attached as Exhibit 99.5 hereto and incorporated herein by reference. | ||||